GLP-1 is a high-purity peptide offered in a 10mg lyophilized powder format, intended strictly for laboratory research and development purposes. Manufactured to exceed 99% purity and tested using both HPLC and LC-MS protocols, this peptide is supplied in a sterile, sealed vial to ensure stability and integrity.
Recent research & studies
- Discontinuation One Week Recommendations for GLP-1 Receptor Agonists Prior to Esophagogastroduodenoscopy.
This study aims to evaluate the impact of a one-week discontinuation of long-acting glucagon-like peptide-1 receptor agonists (GLP-1 RAs) prior to Esophagogastroduodenoscopy on gastric preparation quality and the need for repeat esophagogastroduodenoscopy (EGD), in order to determine whether a one-week…
- A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for…
- A Study of SYH2082 Injection in Healthy Participants
To evaluate the safety and tolerability of single dose of SYH2082 Injection in healthy participants.
- A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes
The study is being conducted to evaluate the efficacy and safety of HRS9531 once weekly (QW) in subjects with type 2 diabetes mellitus not adequately controlled with metformin monotherapy or in combination with SGLT2 inhibitors compared to Semaglutide QW for…
- Discontinuation Recommendations for GLP-1 Receptor Agonists Prior to Colonoscopy: A Randomized Controlled Trial in Taiwan.
This study aims to evaluate the impact of different discontinuation intervals of GLP-1 receptor agonists prior to colonoscopy on bowel preparation quality and the need for repeat colonoscopy, in order to establish appropriate discontinuation recommendations.
- Design of a metabolically-stable peptide therapeutic with triple-hormone-receptor agonist activity.
Peptide-based therapeutics such as tirzepatide and semaglutide target the neuroendocrine system to remediate both diabetes and obesity. In addition to integrating the complementary actions of two endogenous metabolically related hormones targeting glucagon-like peptide-1 and glucagon receptors (GLP-1R and GCGR), the…
These are third-party research studies presented for informational purposes. They are not endorsements and do not constitute medical advice or claims about any product.
